does glp 1 target visceral fat The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management | Current Cardiovascular Risk Reports Frontiers | GLP−1 receptor agonists

However, gastrointestinal symptoms are the main reason why patients decide to end treatment

[cited 2025 Dec 5]

Part of that is due to fact that some of the obesity-associated cancers develop in female sex organs, but the precise reason for this result is not entirely clear

Tirzepatide, sold as Mounjaro, is a different molecule and is not part of the same patent expiry story

It showed that there are significant differences between the two groups in terms of their antioxidant enzyme conditions

Phase 2 CagriSema in T2D (Frias et al., 2023): CagriSema produced superior weight loss and glycemic improvement vs either monotherapy over 32 weeks